Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile

Update on antiphospholipid syndrome.

This review addresses new clinical issues (revealed at the 2006 Sydney update of the 1999 Sapporo Classification criteria; cardiac, renal, and multiple sclerosis-like disease; catastrophic syndrome), mechanisms of action of antiphospholipid antibody (very likely complement mediated), current therapies (moderate dose warfarin recommended for prophylaxis, aspirin not recommended for primary proph...

Anticardiolipin syndrome: antiphospholipid syndrome.

North Am 2000;26:215–27. 14 Savill J. Recognition and phagocytosis of cells undergoing apoptosis. Br Med Bull 1997;53:491–508. 15 Elkon KB. Apoptosis in SLE – too little or too much? Review. Clin Exp Rheumatol 1994;12:553–9. 16 Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene-mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmu...

Antiphospholipid syndrome

APS can be primary or secondary. Primary antiphospholipid syndrome occurs in the absence of any other related disease. Secondary antiphospholipid syndrome is often associated with systemic lupus erythematosus and less frequently with infections, drugs and other diseases. Serologic markers are antiphospholipid antibodies, lupus anticoagulant and anticardiolipin. In rare cases, APS leads to rapid...

Antiphospholipid syndrome

Antiphospholipid syndrome

The antiphospholipid syndrome (APS) is defined by the development of venous and/or arterial thromboses, often multiple, and pregnancy morbidity (mainly, recurrent fetal losses), in the presence of antiphospholipid antibodies (aPL). Some estimates indicate that the incidence of the APS is around 5 new cases per 100,000 persons per year and the prevalence around 40-50 cases per 100,000 persons. T...